Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

INTRODUCTION: Baricitinib, an orally available small-molecule inhibitor of Janus kinase (JAK)1 and JAK2, is indicated to treat active moderate-to-severe rheumatoid arthritis (RA). OBJECTIVE: This systematic review described the real-world clinical characteristics of baricitinib-treated patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Cruz, Blanca, Kiltz, Uta, Avouac, Jérôme, Treuer, Tamas, Haladyj, Ewa, Gerwien, Jens, Gupta, Chandreyee Dutta, Conti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654279/
https://www.ncbi.nlm.nih.gov/pubmed/37715917
http://dx.doi.org/10.1007/s40744-023-00591-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654279/
https://www.ncbi.nlm.nih.gov/pubmed/37715917
http://dx.doi.org/10.1007/s40744-023-00591-9

Ejemplares similares